Plasma concentrations of 9-deoxo-16-dimethyl-9-methylene-PGE2 in rhesus monkeys after administration by various routes.
A method is described for the estimation of 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 by double antibody radioimmunoassay. Plasma samples obtained from animals treated with 9-methylene-16, 16-dimethyl-PGE2, 1-adamantanamic salt were extracted with diethyl ether to recover the prostaglandin. The validation of sample preparation and assay procedure are presented. Rhesus females were treated by several routes of administration and the samples assayed for drug content. Maximum blood levels were probably reached 30 minutes following subcutaneous injection and within 30 seconds of an intravenous injection. Results of the acute intravenous injection indicate an initial half-life of approximately one minute in peripheral circulation. Continuous intravenous infusion at 3 increasing doses of this compound resulted in a stepwise increase in plasma drug concentrations. Vaginal administration of 9-methylene-16, 16-dimethyl-PGE2, 1-adamantanamine salt in suppositories produced a dose dependent increase in plasma drug concentration. Higher plasma drug concentrations were produced when the prostaglandin was delivered in H-15 base suppositories than in E-76 base suppositories.
D015064:16,16-Dimethylprostaglandin E2 / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood*; D000818:Animals; D005260:Female; D008253:Macaca mulatta; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000097:blood*; D011817:Rabbits / Q000276:immunology; D011863:Radioimmunoassay / Q000379:methods; D013488:Suppositories
D011459:Prostaglandins E, Synthetic; D013488:Suppositories; C025505:meteneprost; D015064:16,16-Dimethylprostaglandin E2